Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December
2018
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
14 December 2018 07:00 GMT
NON-EXECUTIVE BOARD CHANGES
AstraZeneca
PLC (the Company) today announced the following changes in respect
of Non-Executive Directors.
New Non-Executive Director
With
effect from 1 January 2019, Professor Tony Mok is appointed as a
Non-Executive Director and a member of the Science Committee.
Biographical details for Professor Mok are provided
below.
Retirement of Non-Executive Director
The
Company previously announced that Shriti Vadera will retire as a
Director by 31 December 2018, by when she will have served as a
Board member for eight years. The Company now confirms she will
leave the Board on 31 December 2018.
Leif
Johansson, Chairman of AstraZeneca, said: "We are very pleased to
welcome Tony Mok to our Board and Science Committee as a leading
clinical oncologist and world-renowned expert in precision medicine
for lung cancer. He will make a significant contribution to
AstraZeneca's science-led transformation as we bring our science to
more patients around the world.
"Shriti
Vadera's eight years with the Company has included service as a
member of both the Audit Committee and the Remuneration Committee.
She has been an exceptional colleague during a period of pipeline
renewal, as AstraZeneca returned to growth. Her diligence, focus
and constant commitment to the Company's success will be missed. On
behalf of all her Board colleagues, we thank her for her service
and wish her every success in the future."
Biographical details - Professor Tony Mok BMSc, MD, FRCP(C),
FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO
Professor
Tony S K Mok was trained at the University of Alberta, Canada and
subsequently completed a fellowship in medical oncology at the
Princess Margaret Hospital in Toronto. After working as a community
oncologist in Toronto, Canada for seven years, he returned to Hong
Kong in 1996 to pursue an academic career.
Professor
Mok is the Li Shu Fan Medical Foundation endowed Professor and
Chairman of the Department of Clinical Oncology at the Chinese
University of Hong Kong. His main research interest focuses on
biomarker and molecular targeted therapy in lung cancer. He was the
principal investigator and first author on the landmark
Iressa Pan-Asia Study
(IPASS), which was the first trial that confirmed the application
of precision medicine for advanced lung cancer. He has led and
co-led multiple other international Phase III trials, addressing
various aspects of the management of advanced lung cancer. His work
also includes clinical research on oncogene driven lung cancer and
immunotherapy and he contributes to the development of clinical
research infrastructure in China and Asia. He co-founded the Lung
Cancer Research Group, the Chinese Thoracic Oncology Research Group
and the Asia Thoracic Oncology Research Group.
Professor
Mok has contributed to over 250 articles in international
peer-reviewed journals, including the New England Journal of
Medicine, Science, Lancet, Nature Medicine and Journal of Clinical
Oncology, and published multiple editorials and textbooks. He is
the past-President and current Treasurer of the International
Association for the Study of Lung Cancer (IASLC) and serves on the
Board of Directors of the American Society of Clinical Oncology
(ASCO).
His
work has been recognised by numerous awards including the Bonnie
Addario Award in 2015, Fellowship of the American Society of
Clinical Oncology (FASCO) in 2017, the Paul Bunn Jr Scientific
Award in 2017, the National Science and Technology Progress Award
in 2017 and the ESMO Lifetime Achievement Award in
2018.
Professor
Mok is a Non-Executive Director of Hutchison China MediTech Limited
and a co-founder and the Chairman of Sanomics Limited.
In
relation to Professor Mok's appointment, except as set out above,
no disclosure obligations arise under paragraphs (1) to (6) of LR
9.6.13 R of the UK Listing Authority's Listing Rules.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide.
For more information, please visit www.astrazeneca.com
and follow us on Twitter
@AstraZeneca.
|
Media
Relations
|
|
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
|
Jennifer
Hursit
|
UK/Global
|
+44
7384 799 726
|
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
Cardiovascular;
Metabolism
|
+44 203
749 5711
|
|
Nick
Stone
|
Respiratory;
Renal
|
+44 203
749 5716
|
|
Josie
Afolabi
|
Other
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance;
Fixed Income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Retail
Investors
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 7277
|
|
|
|
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
14 December
2018
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|